1. As of noon trading, Celgene Corporation ( CELG) is up $3.31 (3.3%) to $104.35 on average volume Thus far, 2.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $100.85-$104.72 after having opened the day at $101.05 as compared to the previous trading day's close of $101.04. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $41.6 billion and is part of the drugs industry. The company has a P/E ratio of 30.1, above the S&P 500 P/E ratio of 17.7. Shares are up 26.7% year to date as of the close of trading on Wednesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD). A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.